{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T21:31:16Z","timestamp":1794951076102,"version":"4.9.1"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T00:00:00Z","timestamp":1743724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T00:00:00Z","timestamp":1743724800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002969","name":"Technologick\u00e1 Agentura \u010cesk\u00e9 Republiky","doi-asserted-by":"publisher","award":["TJ04000129"],"award-info":[{"award-number":["TJ04000129"]}],"id":[{"id":"10.13039\/501100002969","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002969","name":"Technologick\u00e1 Agentura \u010cesk\u00e9 Republiky","doi-asserted-by":"publisher","award":["TO01000074"],"award-info":[{"award-number":["TO01000074"]}],"id":[{"id":"10.13039\/501100002969","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002969","name":"Technologick\u00e1 Agentura \u010cesk\u00e9 Republiky","doi-asserted-by":"publisher","award":["TN02000109"],"award-info":[{"award-number":["TN02000109"]}],"id":[{"id":"10.13039\/501100002969","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007655","name":"\u010cesk\u00e9 Vysok\u00e9 U\u010den\u00ed Technick\u00e9 v Praze","doi-asserted-by":"publisher","award":["SGS22\/188\/OHK4\/3T\/14"],"award-info":[{"award-number":["SGS22\/188\/OHK4\/3T\/14"]}],"id":[{"id":"10.13039\/100007655","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001823","name":"Ministerstvo \u0160kolstv\u00ed, Ml\u00e1de\u017ee a T\u011blov\u00fdchovy","doi-asserted-by":"publisher","award":["8J20PL016"],"award-info":[{"award-number":["8J20PL016"]}],"id":[{"id":"10.13039\/501100001823","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001823","name":"Ministerstvo \u0160kolstv\u00ed, Ml\u00e1de\u017ee a T\u011blov\u00fdchovy","doi-asserted-by":"publisher","award":["CZ.02.01.01\/00\/22_008\/0004644"],"award-info":[{"award-number":["CZ.02.01.01\/00\/22_008\/0004644"]}],"id":[{"id":"10.13039\/501100001823","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001823","name":"Ministerstvo \u0160kolstv\u00ed, Ml\u00e1de\u017ee a T\u011blov\u00fdchovy","doi-asserted-by":"publisher","award":["LM2023053"],"award-info":[{"award-number":["LM2023053"]}],"id":[{"id":"10.13039\/501100001823","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009553","name":"Agentura Pro Zdravotnick\u00fd V\u00fdzkum \u010cesk\u00e9 Republiky","doi-asserted-by":"publisher","award":["NU23 08 00214"],"award-info":[{"award-number":["NU23 08 00214"]}],"id":[{"id":"10.13039\/501100009553","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Internal Grant Agency of Palacky University","award":["IGA LF UP 2024_007"],"award-info":[{"award-number":["IGA LF UP 2024_007"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["EJNMMI radiopharm. chem."],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Overexpression of human epidermal growth factor receptor type 2 (HER2) occurs in multiple carcinomas. For example, up to 20% of breast cancer cases are classified as HER2 positive (HER2+). Treatment of this condition typically involves immunotherapy using monoclonal antibodies, such as trastuzumab or pertuzumab. The precise targeting of monoclonal antibodies to HER2+\u2009tumour lesions can be used as well in radioimmunotherapy to deliver medical radionuclides exactly to the afflicted area and therefore minimize radiation exposure of healthy tissues. In this study, DOTA conjugates of monoclonal antibodies trastuzumab and pertuzumab were prepared and tested in vitro. One of these, <jats:sup>225<\/jats:sup>Ac-DOTA-pertuzumab, was also the subject of an ex vivo biodistribution study with normal as well as HER2+\u2009and HER2- tumour-xenografted mice. This radioconjugate has not been previously described.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Three DOTA-conjugates of HER2 targeting monoclonal antibodies, one of trastuzumab and two of pertuzumab, were prepared and radiolabelled with <jats:sup>225<\/jats:sup>Ac in different molar ratios. This procedure led to an optimisation of the preparation and radiolabelling process. The radioconjugates were shown to be highly stable in vitro in both fetal bovine serum and phosphate buffered saline under room temperature and decreased temperature for 10\u00a0days. In vitro cell studies with HER2-overexpressing cell-line (SKOV-3) and low HER2-expressing cell line (MDA-MB-231) proved that radioconjugates of both antibodies have high binding specificity and affinity towards HER2 receptors. These findings were confirmed for a novel radioconjugate <jats:sup>225<\/jats:sup>Ac-DOTA-pertuzumab in an ex vivo biodistribution study, where uptake in HER2+\u2009tumour was 50\u2009\u00b1\u200914% ID\/g and HER2- tumour showed uptake comparable with healthy tissues (max.\u00a05.0\u2009\u00b1\u20091.7% ID\/g). The high uptake observed in the spleen can be attributed to the elimination of the antibody, as well as the use of an immunedeficient mouse strain (SCID).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>During this study, the optimization of preparation and radiolabelling of HER2 targeting antibodies with <jats:sup>225<\/jats:sup>Ac was accomplished. Furthermore, the radioconjugate <jats:sup>225<\/jats:sup>Ac-DOTA-pertuzumab was prepared and evaluated for the first time. The radioconjugates of both tested antibodies demonstrated excellent qualities in terms of stability and HER2 receptor affinity. Initial ex vivo studies indicated that especially the radioconjugate <jats:sup>225<\/jats:sup>Ac-DOTA-pertuzumab is a very promising candidate for further more detailed in vivo studies.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s41181-025-00337-8","type":"journal-article","created":{"date-parts":[[2025,4,5]],"date-time":"2025-04-05T03:00:59Z","timestamp":1743822059000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["In vitro and in vivo evaluation of anti-HER2 antibody conjugates labelled with 225Ac"],"prefix":"10.1186","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7317-1503","authenticated-orcid":false,"given":"Kate\u0159ina","family":"Ondr\u00e1k Fialov\u00e1","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8070-8081","authenticated-orcid":false,"given":"Luk\u00e1\u0161","family":"Ondr\u00e1k","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1044-1910","authenticated-orcid":false,"given":"Martin","family":"Vlk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6315-9225","authenticated-orcid":false,"given":"J\u00e1n","family":"Kozempel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate\u0159ina","family":"Nov\u00e1kov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7716-2142","authenticated-orcid":false,"given":"Zbyn\u011bk","family":"Nov\u00fd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-3078-0907","authenticated-orcid":false,"given":"Katar\u00edna","family":"Hajduov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4834-908X","authenticated-orcid":false,"given":"Mari\u00e1n","family":"Hajd\u00fach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1334-5916","authenticated-orcid":false,"given":"Milo\u0161","family":"Pet\u0159\u00edk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marek","family":"Pruszynski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Bruchertseifer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfred","family":"Morgenstern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,4]]},"reference":[{"key":"337_CR1","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/2191-219X-1-18","volume":"1","author":"N Abbas","year":"2011","unstructured":"Abbas N, Heyerdahl H, Bruland OS, Borreb\u00e6k J, Nesland J, Dahle J. Experimental \u03b1-particle radioimmunotherapy of breast cancer using 227Th-labeled p-benzyl-DOTA-trastuzumab. EJNMMI Res. 2011;1:18.","journal-title":"EJNMMI Res"},{"key":"337_CR2","doi-asserted-by":"publisher","first-page":"23","DOI":"10.3390\/cancers16010023","volume":"16","author":"V Angelis","year":"2024","unstructured":"Angelis V, Okines AFC. Systemic therapies for HER2-positive advanced breast cancer. Cancers. 2024;16:23.","journal-title":"Cancers"},{"key":"337_CR3","doi-asserted-by":"publisher","first-page":"35419","DOI":"10.18632\/oncotarget.6214","volume":"6","author":"A Beheshti","year":"2015","unstructured":"Beheshti A, Wage J, McDonald JT, Lamont C, Peluso M, Hahnfeldt P, et al. Tumor-host signaling interaction reveals a systemic, age-dependent splenic immune influence on tumor development. Oncotarget. 2015;6:35419\u201332.","journal-title":"Oncotarget"},{"key":"337_CR4","doi-asserted-by":"publisher","first-page":"2300","DOI":"10.1007\/s00259-018-4099-8","volume":"45","author":"F Bensch","year":"2018","unstructured":"Bensch F, Brouwers AH, Lub-de Hooge MN, de Jong JR, van der Vegt B, Sleijfer S, et al. 89Zr-trastuzumab PET supports clinical decision making in breast cancer patients, when HER2 status cannot be determined by standard work up. Eur J Nucl Med Mol Imaging. 2018;45:2300\u201323.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"337_CR5","first-page":"5084","volume":"63","author":"PE Borchardt","year":"2003","unstructured":"Borchardt PE, Yuan RR, Miederer M, McDevitt MR, Scheinberg DA. Targeted actinium-225 in vivo generators for therapy of ovarian cancer. Cancer Res. 2003;63:5084\u201390.","journal-title":"Cancer Res"},{"key":"337_CR6","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1016\/j.immuni.2013.10.010","volume":"39","author":"V Bronte","year":"2013","unstructured":"Bronte V, Pittet MJ. The spleen in local and systemic regulation of immunity. Immunity. 2013;39:806\u201318.","journal-title":"Immunity"},{"key":"337_CR7","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.cbpa.2021.06.008","volume":"63","author":"DM Chigoho","year":"2021","unstructured":"Chigoho DM, Bridoux J, Hernot S. Reducing the renal retention of low- to moderate-molecular-weight radiopharmaceuticals. Curr Opin Chem Biol. 2021;63:219\u201328.","journal-title":"Curr Opin Chem Biol"},{"key":"337_CR8","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1021\/acs.bioconjchem.1c00136","volume":"32","author":"M Chomet","year":"2021","unstructured":"Chomet M, van Dongen GAMS, Vugts DJ. State of the art in radiolabeling of antibodies with common and uncommon radiometals for preclinical and clinical immuno-PET. Bioconjug Chem. 2021;32:1315\u201330.","journal-title":"Bioconjug Chem"},{"key":"337_CR9","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.3390\/ijms241512031","volume":"24","author":"VL Cruz","year":"2023","unstructured":"Cruz VL, Souza-Egipsy V, Gion M, P\u00e9rez-Garc\u00eda J, Cortes J, Ramos J, et al. Binding affinity of trastuzumab and pertuzumab monoclonal antibodies to extracellular HER2 domain. Int J Mol Sci. 2023;24:1203.","journal-title":"Int J Mol Sci"},{"key":"337_CR10","doi-asserted-by":"publisher","first-page":"64431","DOI":"10.18632\/oncotarget.7043","volume":"7","author":"GD de Melo","year":"2016","unstructured":"de Melo GD, Jardim DL, Marchesi MS, Hortobagyi GN. Mechanisms of resistance and sensitivity to anti-HER2 therapies in HER2+ breast cancer. Oncotarget. 2016;7:64431\u201346.","journal-title":"Oncotarget"},{"key":"337_CR11","doi-asserted-by":"publisher","first-page":"256","DOI":"10.3390\/ph17020256","volume":"16","author":"KE de Roode","year":"2024","unstructured":"de Roode KE, Joosten L, Behe M. Towards the magic radioactive bullet: improving targeted radionuclide therapy by reducing the renal retention of radioligands. Pharmaceuticals. 2024;16:256.","journal-title":"Pharmaceuticals"},{"key":"337_CR12","doi-asserted-by":"publisher","first-page":"2988","DOI":"10.1021\/jm990141f","volume":"42","author":"KA Deal","year":"1999","unstructured":"Deal KA, Davis IA, Mirzadeh S, Kennel SJ, Brechbiel MW. Improved in vivo stability of actinium-225 macrocyclic complexes. J Med Chem. 1999;42:2988\u201392.","journal-title":"J Med Chem"},{"key":"337_CR13","doi-asserted-by":"publisher","first-page":"3553","DOI":"10.1021\/acs.molpharmaceut.0c00580","volume":"17","author":"Y Dekempeneer","year":"2020","unstructured":"Dekempeneer Y, Caveliers V, Ooms M, Maertens D, Gysemans M, Lahoutte T, et al. Therapeutic efficacy of 213Bi-labeled sdAbs in a preclinical model of ovarian cancer. Mol Pharm. 2020;17:3553\u201366.","journal-title":"Mol Pharm"},{"key":"337_CR14","doi-asserted-by":"publisher","first-page":"974","DOI":"10.2967\/jnumed.108.060392","volume":"50","author":"EC Dijkers","year":"2009","unstructured":"Dijkers EC, Kosterink JG, Rademaker AP, Perk LR, van Dongen GA, Bart J, et al. Development and characterization of clinical-grade 89Zr-trastuzumab for HER2\/neu immunoPET imaging. J Nucl Med. 2009;50:974\u201381.","journal-title":"J Nucl Med"},{"key":"337_CR15","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1038\/nri3175","volume":"12","author":"DI Gabrilovich","year":"2012","unstructured":"Gabrilovich DI, Ostrand-Rosenberg S, Bronte V. Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol. 2012;12:253\u201368.","journal-title":"Nat Rev Immunol"},{"key":"337_CR16","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1039\/D0MD00319K","volume":"12","author":"M Guleria","year":"2020","unstructured":"Guleria M, Sharma R, Amirdhanayagam J, Sarma HD, Rangarajan V, Dash A, et al. Formulation and clinical translation of [177Lu]Lu-trastuzumab for radioimmunotheranostics of metastatic breast cancer. RSC Med Chem. 2020;12:263\u201377.","journal-title":"RSC Med Chem"},{"key":"337_CR17","doi-asserted-by":"publisher","first-page":"114","DOI":"10.3390\/ph12030114","volume":"12","author":"U Hennrich","year":"2019","unstructured":"Hennrich U, Kopka K. Lutathera\u00ae: the first FDA- and EMA-approved radiopharmaceutical for peptide receptor radionuclide therapy. Pharmaceuticals. 2019;12:114.","journal-title":"Pharmaceuticals"},{"key":"337_CR18","doi-asserted-by":"publisher","first-page":"2469","DOI":"10.1002\/cam4.842","volume":"5","author":"A Hodgson","year":"2016","unstructured":"Hodgson A, Wier EM, Fu K, Sun X, Wan F. Ultrasound imaging of splenomegaly as a proxy to monitor colon tumor development in Apc(min716\/+) mice. Cancer Med. 2016;5:2469\u201376.","journal-title":"Cancer Med"},{"key":"337_CR19","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s41181-024-00239-1","volume":"9","author":"EL Hooijman","year":"2024","unstructured":"Hooijman EL, Radchenko V, Ling SW, Konijnenberg M, Brabander T, Koolen SLW, et al. Implementing Ac-225 labelled radiopharmaceuticals: practical considerations and (pre-)clinical perspectives. EJNMMI Radiopharm Chem. 2024;9:9.","journal-title":"EJNMMI Radiopharm Chem"},{"issue":"1","key":"337_CR20","first-page":"852748","volume":"2014","author":"N Iqbal","year":"2014","unstructured":"Iqbal N, Iqbal N. Human epidermal growth factor receptor 2 (HER2) in Cancers: overexpression and therapeutic implications. Mol Biol Int. 2014;2014(1):852748.","journal-title":"Mol Biol Int"},{"key":"337_CR21","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.3390\/pharmaceutics14071338","volume":"14","author":"M Kang","year":"2022","unstructured":"Kang M, Shin JI, Han S, Kim JY, Park J, Kim KI, et al. Therapeutic response monitoring with 89Zr-DFO-pertuzumab in HER2-positive and trastuzumab-resistant breast cancer models. Pharmaceutics. 2022;14:1338.","journal-title":"Pharmaceutics"},{"key":"337_CR22","doi-asserted-by":"publisher","first-page":"6419","DOI":"10.1021\/acs.jmedchem.1c02044","volume":"65","author":"U Karczmarczyk","year":"2022","unstructured":"Karczmarczyk U, Sawicka A, Garnuszek P, Maurin M, Wojdowska W. Does the number of bifunctional chelators conjugated to a mAb affect the biological activity of its radio-labeled counterpart? Discussion using the example of mAb against CD-20 labeled with 90Y or 177Lu. J Med Chem. 2022;65:6419\u201330.","journal-title":"J Med Chem"},{"key":"337_CR23","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s41181-023-00208-0","volume":"8","author":"M Kondo","year":"2023","unstructured":"Kondo M, Cai Z, Chan C, Forkan N, Reilly RM. [225Ac]Ac- and [111In]In-DOTA-trastuzumab theranostic pair: cellular dosimetry and cytotoxicity in vitro and tumour and normal tissue uptake in vivo in NRG mice with HER2-positive human breast cancer xenografts. EJNMMI Radiopharm Chem. 2023;8:24.","journal-title":"EJNMMI Radiopharm Chem"},{"key":"337_CR24","doi-asserted-by":"publisher","first-page":"2106","DOI":"10.1007\/s00259-014-2857-9","volume":"41","author":"C Kratochwil","year":"2014","unstructured":"Kratochwil C, Giesel FL, Bruchertseifer F, Mier W, Apostolidis C, Boll R, et al. 213Bi-DOTATOC receptor-targeted alpha-radionuclide therapy induces remission in neuroendocrine tumours refractory to beta radiation: a first-in-human experience. Eur J Nucl Med Mol Imaging. 2014;41:2106\u201319.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"337_CR25","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.2967\/jnumed.116.178673","volume":"57","author":"C Kratochwil","year":"2016","unstructured":"Kratochwil C, Bruchertseifer F, Giesel FL, Weis M, Verburg FA, Mottaghy F, et al. 225Ac-PSMA-617 for PSMA-targeted \u03b1-radiation therapy of metastatic castration-resistant prostate cancer. J Nucl Med. 2016;57:1941\u20134.","journal-title":"J Nucl Med"},{"key":"337_CR26","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.2967\/jnumed.117.191395","volume":"58","author":"C Kratochwil","year":"2017","unstructured":"Kratochwil C, Bruchertseifer F, Rathke H, Bronzel M, Apostolidis C, Weichert W, et al. Targeted \u03b1-therapy of metastatic castration-resistant prostate cancer with 225Ac-PSMA-617: dosimetry estimate and empiric dose finding. J Nucl Med. 2017;58:1624\u201331.","journal-title":"J Nucl Med"},{"key":"337_CR27","first-page":"1045","volume":"10","author":"J Kreutzfeldt","year":"2020","unstructured":"Kreutzfeldt J, Rozeboom B, Dey N, De P. The trastuzumab era: current and upcoming targeted HER2+ breast cancer therapies. Am J Cancer Res. 2020;10:1045\u201367.","journal-title":"Am J Cancer Res"},{"issue":"Suppl 2","key":"337_CR28","first-page":"632","volume":"57","author":"L Krolicki","year":"2016","unstructured":"Krolicki L, Morgenstern A, Kunikowska J, Koziara H, Krolicki B, Jakucinski M, et al. Alpha therapy with 213Bi-DOTA-substance P in recurrent glioblastoma multiforme. J Nucl Med. 2016;57(Suppl 2):632.","journal-title":"J Nucl Med"},{"key":"337_CR29","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1038\/nrc3925","volume":"15","author":"S Larson","year":"2015","unstructured":"Larson S, Carrasquillo J, Cheung NK, Press OW. Radioimmunotherapy of human tumours. Nat Rev Cancer. 2015;15:347\u201360.","journal-title":"Nat Rev Cancer"},{"key":"337_CR30","first-page":"1454","volume":"9","author":"HJ Lee","year":"2019","unstructured":"Lee HJ, Ehlerding EB, Jiang D, Barnhart TE, Cao T, Wei W, et al. Dual-labeled pertuzumab for multimodality image-guided ovarian tumor resection. Am J Cancer Res. 2019;9:1454\u201368.","journal-title":"Am J Cancer Res"},{"key":"337_CR31","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.2967\/jnumed.120.249300","volume":"62","author":"HK Li","year":"2021","unstructured":"Li HK, Morokoshi Y, Kodaira S, Kusumoto T, Minegishi K, Kanda H, et al. Utility of 211At-trastuzumab for the treatment of metastatic gastric cancer in the liver: evaluation of a preclinical \u03b1-radioimmunotherapy approach in a clinically relevant mouse model. J Nucl Med. 2021;62:1468\u201374.","journal-title":"J Nucl Med"},{"key":"337_CR32","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1038\/s41598-017-18892-9","volume":"8","author":"WH Lua","year":"2018","unstructured":"Lua WH, Ling WL, Yeo JY, Poh JJ, Lane DP, Gan SK. The effects of antibody engineering CH and CL in trastuzumab and pertuzumab recombinant models: Impact on antibody production and antigen-binding. Sci Rep. 2018;8:718.","journal-title":"Sci Rep"},{"key":"337_CR33","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/sj.bjp.0705915","volume":"143","author":"MN Lub-de Hooge","year":"2004","unstructured":"Lub-de Hooge MN, Kosterink JG, Perik PJ, Nijnuis H, Tran L, Bart J, et al. Preclinical characterisation of 111In-DTPA-trastuzumab. Br J Pharmacol. 2004;143:99\u2013106.","journal-title":"Br J Pharmacol"},{"key":"337_CR34","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.2967\/jnumed.114.138347","volume":"55","author":"WF Maguire","year":"2014","unstructured":"Maguire WF, McDevitt MR, Smith-Jones PM, Scheinberg DA. Efficient one-step radiolabeling of monoclonal antibodies to high specific activity with actinium-225 for \u03b1-particle radioimmunotherapy of cancer. J Nucl Med. 2014;55:1492\u20138.","journal-title":"J Nucl Med"},{"key":"337_CR35","doi-asserted-by":"publisher","first-page":"3988","DOI":"10.1021\/mp500323d","volume":"11","author":"BV Marquez","year":"2014","unstructured":"Marquez BV, Ikotun OF, Zheleznyak A, Wright B, Hari-Raj A, Pierce RA, et al. Evaluation of 89Zr-pertuzumab in Breast cancer xenografts. Mol Pharm. 2014;11:3988\u201395.","journal-title":"Mol Pharm"},{"key":"337_CR36","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1126\/science.1064126","volume":"294","author":"MR McDevitt","year":"2001","unstructured":"McDevitt MR, Ma D, Lai LT, Simon J, Borchardt P, Frank RK, et al. Tumor therapy with targeted atomic nanogenerators. Science. 2001;294:1537\u201340.","journal-title":"Science"},{"key":"337_CR37","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/S0969-8043(02)00167-7","volume":"57","author":"MR McDevitt","year":"2002","unstructured":"McDevitt MR, Ma D, Simon J, Frank RK, Scheinberg DA. Design and synthesis of 225Ac radioimmunopharmaceuticals. Appl Radiat Isot. 2002;57:841\u20137.","journal-title":"Appl Radiat Isot"},{"key":"337_CR38","first-page":"384","volume":"37","author":"SR Menon","year":"2022","unstructured":"Menon SR, Mitra A, Chakraborty A, Tawate M, Sahu S, Rakshit S, et al. Clinical dose preparation of [177Lu]Lu-DOTA-pertuzumab using medium specific activity [177Lu]LuCl3 for radioimmunotherapy of breast and epithelial ovarian cancers, with HER2 receptor overexpression. Cancer Biother Radiopharm. 2022;37:384\u2013402.","journal-title":"Cancer Biother Radiopharm"},{"issue":"31","key":"337_CR39","doi-asserted-by":"publisher","first-page":"21978","DOI":"10.18632\/oncotarget.25140","volume":"9","author":"B Mertens","year":"2018","unstructured":"Mertens B, de Araujo Nogueira TC, Topalis D, Stranska R, Snoeck R, Andrei G. Investigation of tumor-tumor interactions in a double human cervical carcinoma xenograft model in nude mice. Oncotarget. 2018;9(31):21978.","journal-title":"Oncotarget"},{"key":"337_CR40","first-page":"557","volume":"20","author":"DE Milenic","year":"2005","unstructured":"Milenic DE, Garmestani K, Brady ED, Albert PS, Ma D, Abdulla A, et al. Alpha-particle radioimmunotherapy of disseminated peritoneal disease using a (212)Pb-labeled radioimmunoconjugate targeting HER2. Cancer Biother Radiopharm. 2005;20:557\u201368.","journal-title":"Cancer Biother Radiopharm"},{"issue":"1","key":"337_CR41","first-page":"743193","volume":"2012","author":"Z Mitri","year":"2012","unstructured":"Mitri Z, Constantine T, O\u2019Regan R. The HER2 receptor in breast cancer: pathophysiology, clinical use, and new advances in therapy. Chemother Res Pract. 2012;2012(1):743193.","journal-title":"Chemother Res Pract"},{"key":"337_CR42","doi-asserted-by":"publisher","first-page":"200","DOI":"10.2174\/1874471011666180502104524","volume":"11","author":"A Morgenstern","year":"2018","unstructured":"Morgenstern A, Apostolidis C, Kratochwil C, Sathekde M, Krolicki L, Bruchertseifer F. An overview of targeted alpha therapy with 225Actinium and 213Bismuth. Curr Radiopharm. 2018;11:200\u20138.","journal-title":"Curr Radiopharm"},{"key":"337_CR43","doi-asserted-by":"publisher","first-page":"e149","DOI":"10.1097\/RLU.0000000000005067","volume":"49","author":"YS Narwadkar","year":"2024","unstructured":"Narwadkar YS, Parghane RV, Sahu S, Lad S, Deep K, Wanage G, et al. Clinical Internal dosimetry and biodistribution of 177Lu-DOTA-trastuzumab in HER2-positive metastatic and locally advanced breast carcinoma. Clin Nucl Med. 2024;49:e149\u201355.","journal-title":"Clin Nucl Med"},{"issue":"Suppl 1","key":"337_CR44","doi-asserted-by":"publisher","first-page":"S9","DOI":"10.1093\/annonc\/12.suppl_1.S9","volume":"12","author":"RM Neve","year":"2001","unstructured":"Neve RM, Lane HA, Hynes NE. The role of overexpressed HER2 in transformation. Ann Oncol. 2001;12(Suppl 1):S9-13.","journal-title":"Ann Oncol"},{"key":"337_CR45","doi-asserted-by":"publisher","first-page":"161","DOI":"10.2967\/jnumed.117.194555","volume":"59","author":"JA O'Donoghue","year":"2018","unstructured":"O\u2019Donoghue JA, Lewis JS, Pandit-Taskar N, Fleming SE, Sch\u00f6der H, Larson SM, et al. Pharmacokinetics, biodistribution, and radiation dosimetry for 89Zr-trastuzumab in patients with esophagogastric cancer. J Nucl Med. 2018;59:161\u20136.","journal-title":"J Nucl Med"},{"key":"337_CR46","doi-asserted-by":"publisher","first-page":"2276","DOI":"10.1200\/JCO.2005.03.8448","volume":"24","author":"PJ Perik","year":"2006","unstructured":"Perik PJ, Lub-De Hooge MN, Gietema JA, van der Graaf WT, de Korte MA, Jonkman S, et al. Indium-111-labeled trastuzumab scintigraphy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol. 2006;24:2276\u201382.","journal-title":"J Clin Oncol"},{"issue":"4","key":"337_CR47","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1021\/acs.molpharmaceut.7b00985","volume":"15","author":"M Pruszynski","year":"2018","unstructured":"Pruszynski M, D\u2019Huyvetter M, Bruchertseifer F, Morgenstern A, Lahoutte T. Evaluation of an Anti-HER2 nanobody labeled with 225Ac for targeted \u03b1-particle therapy of cancer. Mol Pharm. 2018;15(4):1457\u201366.","journal-title":"Mol Pharm"},{"key":"337_CR48","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.3390\/cancers12041017","volume":"12","author":"J Puttemans","year":"2020","unstructured":"Puttemans J, Dekempeneer Y, Eersels JL, Hanssens H, Debie P, Keyaerts M, et al. Preclinical targeted \u03b1- and \u03b2\u2013radionuclide therapy in HER2-positive brain metastasis using camelid single-domain antibodies. Cancers (Basel). 2020;12:1017.","journal-title":"Cancers (Basel)"},{"key":"337_CR49","doi-asserted-by":"publisher","first-page":"1964","DOI":"10.1016\/j.apradiso.2010.05.004","volume":"68","author":"S Rasaneh","year":"2010","unstructured":"Rasaneh S, Rajabi H, Hossein Babaei M, Johari DF. Toxicity of trastuzumab labeled 177Lu on MCF7 and SKBr 3 cell lines. Appl Radiat Isot. 2010a;68:1964\u20136.","journal-title":"Appl Radiat Isot"},{"key":"337_CR50","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1002\/jlcr.1780","volume":"53","author":"S Rasaneh","year":"2010","unstructured":"Rasaneh S, Rajabi H, Babaei MH, Daha FJ. Synthesis and biodistribution studies of 177Lu-trastuzumab as a therapeutic agent in the breast cancer mice model. J Label Compd Radiopharm. 2010b;53:575\u20139.","journal-title":"J Label Compd Radiopharm"},{"key":"337_CR51","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1158\/1535-7163.MCT-21-1021","volume":"21","author":"M Rodak","year":"2022","unstructured":"Rodak M, Dekempeneer Y, Wojew\u00f3dzka M, Cavaliers V, Covens P, Miller BW, et al. Preclinical evaluation of 225Ac-labeled single-domain antibody for the treatment of HER2pos cancer. Mol Cancer Ther. 2022;21:1835\u201345.","journal-title":"Mol Cancer Ther"},{"key":"337_CR52","doi-asserted-by":"publisher","first-page":"5570","DOI":"10.3390\/cancers13215570","volume":"13","author":"A Rondon","year":"2021","unstructured":"Rondon A, Rouanet J, Degoul F. Radioimmunotherapy in oncology: overview of the last decade clinical trials. Cancers. 2021;13:5570.","journal-title":"Cancers"},{"issue":"Suppl 1","key":"337_CR53","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1093\/annonc\/12.suppl_1.S3","volume":"12","author":"I Rubin","year":"2001","unstructured":"Rubin I, Yarden Y. The basic biology of HER2. Ann Oncol. 2001;12(Suppl 1):S3-8.","journal-title":"Ann Oncol"},{"key":"337_CR54","first-page":"108973","volume":"140\u2013141","author":"M Sakm\u00e1r","year":"2024","unstructured":"Sakm\u00e1r M, Kozempel J, Ku\u010dka J, Jansk\u00e1 T, \u0160t\u00edbr M, Ondr\u00e1k L, et al. In vitro and in vivo study of 221Fr and 213Bi progeny release from the 225Ac-labelled TiO2 nanoparticles. Nucl Med Biol. 2024;140\u2013141:108973.","journal-title":"Nucl Med Biol"},{"key":"337_CR55","doi-asserted-by":"publisher","first-page":"306","DOI":"10.2174\/1874471011104040306","volume":"4","author":"DA Scheinberg","year":"2011","unstructured":"Scheinberg DA, McDevitt MR. Actinium-225 in targeted alpha-particle therapeutic applications. Curr Radiopharm. 2011;4:306\u201320.","journal-title":"Curr Radiopharm"},{"key":"337_CR56","doi-asserted-by":"publisher","first-page":"1820","DOI":"10.1158\/0008-5472.CAN-17-1958","volume":"78","author":"SK Sharma","year":"2018","unstructured":"Sharma SK, Chow A, Monette S, Vivier D, Pourat J, Edwards KJ, et al. Fc-mediated anomalous biodistribution of therapeutic antibodies in immunodeficient mouse models. Cancer Res. 2018;78:1820\u201332.","journal-title":"Cancer Res"},{"key":"337_CR57","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1007\/s11864-023-01137-5","volume":"24","author":"M Stanowicka-Grada","year":"2023","unstructured":"Stanowicka-Grada M, Senkus E. Anti-HER2 drugs for the treatment of advanced HER2 positive breast cancer. Curr Treat Options Oncol. 2023;24:1633\u201350.","journal-title":"Curr Treat Options Oncol"},{"key":"337_CR58","unstructured":"Summary of product characteristics Herceptin, Roche Registration GmBH, 2000. Available from: https:\/\/ec.europa.eu\/health\/documents\/community-register\/2021\/20210901152295\/anx_152295_cs.pdf"},{"key":"337_CR59","unstructured":"Summary of product characteristics Perjeta, Roche Registration GmBH, 2013. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/perjeta-epar-product-information_en.pdf"},{"key":"337_CR60","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1038\/nrc3581","volume":"13","author":"JE Talmadge","year":"2013","unstructured":"Talmadge JE, Gabrilovich DI. History of myeloid-derived suppressor cells. Nat Rev Cancer. 2013;13:739\u201352.","journal-title":"Nat Rev Cancer"},{"key":"337_CR61","first-page":"336","volume":"33","author":"NA Thiele","year":"2018","unstructured":"Thiele NA, Wilson JJ. Actinium-225 for targeted \u03b1 therapy: coordination chemistry and current chelation approaches. Cancer Biother Radiopharm. 2018;33:336\u201348.","journal-title":"Cancer Biother Radiopharm"},{"key":"337_CR62","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1016\/j.celrep.2012.08.006","volume":"2","author":"S Ugel","year":"2012","unstructured":"Ugel S, Peranzoni E, Desantis G, Chioda M, Walter S, Weinschenk T, et al. Immune tolerance to tumor antigens occurs in a specialized environment of the spleen. Cell Rep. 2012;2:628\u201339.","journal-title":"Cell Rep"},{"key":"337_CR63","doi-asserted-by":"publisher","first-page":"900","DOI":"10.2967\/jnumed.117.202010","volume":"59","author":"GA Ulaner","year":"2018","unstructured":"Ulaner GA, Lyashchenko SK, Riedl C, Ruan S, Zanzonico PB, Lake D, et al. First-in-human human epidermal growth factor receptor 2-targeted imaging using 89Zr-pertuzumab PET\/CT: dosimetry and clinical application in patients with breast cancer. J Nucl Med. 2018;59:900\u20136.","journal-title":"J Nucl Med"},{"key":"337_CR64","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/s41392-019-0069-2","volume":"4","author":"J Wang","year":"2019","unstructured":"Wang J, Xu B. Targeted therapeutic options and future perspectives for HER2-positive breast cancer. Signal Transduct Target Ther. 2019;4:34.","journal-title":"Signal Transduct Target Ther"},{"key":"337_CR65","doi-asserted-by":"publisher","first-page":"4880","DOI":"10.1002\/cam4.4818","volume":"11","author":"LS Xiao","year":"2022","unstructured":"Xiao LS, Hu CY, Cui H, Li RN, Hong C, Li QM, et al. Splenomegaly in predicting the survival of patients with advanced primary liver cancer treated with immune checkpoint inhibitors. Cancer Med. 2022;11:4880\u20138.","journal-title":"Cancer Med"},{"key":"337_CR66","doi-asserted-by":"publisher","first-page":"6168","DOI":"10.1039\/c0dt01595d","volume":"40","author":"BM Zeglis","year":"2011","unstructured":"Zeglis BM, Lewis JS. A practical guide to the construction of radiometallated bioconjugates for positron emission tomography. Dalton Trans. 2011;40:6168\u201395.","journal-title":"Dalton Trans"}],"container-title":["EJNMMI Radiopharmacy and Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41181-025-00337-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41181-025-00337-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41181-025-00337-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T10:02:33Z","timestamp":1746093753000},"score":1,"resource":{"primary":{"URL":"https:\/\/ejnmmipharmchem.springeropen.com\/articles\/10.1186\/s41181-025-00337-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,4]]},"references-count":66,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["337"],"URL":"https:\/\/doi.org\/10.1186\/s41181-025-00337-8","relation":{},"ISSN":["2365-421X"],"issn-type":[{"value":"2365-421X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,4]]},"assertion":[{"value":"6 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 May 2025","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The license text has been corrected.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal experiments were done following the regulations and guidelines of the Czech Animal Protection Act (No.246\/1992) and with the approval of Ministry of Education, Youth and Sports of the Czech Republic and the Institutional Animal Welfare Committee of the Faculty of Medicine and Dentistry of Palack\u00fd University in Olomouc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"16"}}